Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

International Journal of Rheumatic Diseases

Volumn 19, Issue 12, 2016, Pages 1216-1225

  Fleischmann, Roy ^a   Kremer, Joel ^b   Tanaka, Yoshiya ^c   Gruben, David ^d   Kanik, Keith ^d   Koncz, Tamas ^d   Krishnaswami, Sriram ^d   Wallenstein, Gene ^d   Wilkinson, Bethanie ^d   Zwillich, Samuel H ^d   Keystone, Edward ^e  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d PFIZER INC   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

efficacy; Phase 2; rheumatoid arthritis; safety; tofacitinib

Indexed keywords

METHOTREXATE; TOFACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

BASAL CELL CARCINOMA; DAS28; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; INFECTIOUS ARTHRITIS; KIDNEY CARCINOMA; LEUKOPENIA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PNEUMONIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MIDDLE AGED; REMISSION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84994452795     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12901     Document Type: Review

References (33)

1. Strand V, Khanna D (2010) The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol 28, S32–40.
2. Smolen JS, Landewé R, Breedveld FC et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69, 964–75.
3. Rezaei H, Saevarsdottir S, Forslind K et al. (2012) In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 71, 186–91.
4. Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64, 625–39.
5. Barton JL (2009) Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 3, 335–44.
6. Felson DT, Smolen JS, Wells G et al. (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63, 573–86.
7. McInnes I, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205–19.
8. Ghoreschi K, Laurence A, O'Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228, 273–87.
9. Fleischmann R (2012) Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 24, 335–41.
10. Meyer DM, Jesson MI, Li X et al. (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7, 41.
11. Fleischmann R, Cutolo M, Genovese MC et al. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64, 617–29.
12. Kremer JM, Bloom BJ, Breedveld FC et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60, 1895–905.
13. Kremer JM, Cohen S, Wilkinson BE et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64, 970–81.
14. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63, 1150–8.
15. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S (2015) Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, Phase 2 study. Mod Rheumatol 25, 514–21.
16. Strand V, Scott DL, Emery P et al. (2005) Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 32, 590–601.
17. Coombs JH, Bloom BJ, Breedveld FC et al. (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 69, 413–6.
18. Woodworth T, Furst DE, Alten R et al. (2007) Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v. 2.0. J Rheumatol 34, 1401–14.
19. Tan H, Gruben D, French J, Thomas N (2011) A case study of model-based Bayesian dose response estimation. Stat Med 30, 2622–33.
20. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37, 269–96.
21. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–85.
22. Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68, 25–32.
23. Curtis JR, Patkar N, Xie A et al. (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56, 1125–33.
24. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54, 2368–76.
25. Kievit W, Fransen J, Adang EM et al. (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50, 196–203.
26. Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63, 1479–85.
27. Saag KG, Teng GG, Patkar NM et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762–84.
28. Burmester GR, Blanco R, Charles-Schoeman C et al. (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451–60.
29. Fleischmann R, Kremer J, Cush J et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367, 495–507.
30. van der Heijde D, Tanaka Y, Fleischmann R et al. (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 559–70.
31. van Vollenhoven RF, Fleischmann R, Cohen S et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 508–19.
32. Kremer J, Li ZG, Hall S et al. (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159, 253–61.
33. Lee EB, Fleischmann R, Hall S et al. (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370, 2377–86.